An oncolytic herpesvirus expressing a CXCR4 antagonist interferes with Glioblastoma cells stemness features and migration

preprint OA: closed
📄 Open PDF Full text JSON View at publisher

Abstract

ABSTRACT Glioblastoma is one of the most aggressive brain tumors. Despite the standard therapy, the survival from diagnosis remains dramatically low, especially due to relapses. Considering their capacity to escape the tumor and to migrate to the subventricular zone through a CXCR4-dependant mechanism, Glioblastoma stem-like cells (GSCs) are considered as responsible for these relapses. CXCR4 regulates biological features associated with tumor progression, including self-renewal, migration and radio-resistance. Importantly, its expression correlates with severity and poor prognosis of several cancers including GBM. CXCR4/CXCL12 pathway appears therefore as an interesting potential therapeutic target. We have generated an oncolytic herpesvirus (oHSV) expressing HA-P2G, a mutated form of CXCL12 previously described as a CXCR4 competitive inhibitor. We demonstrate that in vitro , oHSV/P2G impairs human primary GSCs’ stemness markers expression, self-renewal and migration. In an orthotopic xenograft murine model, its injection within the tumor limits tumor growth and GSCs migration. The ability of P2G to interfere with major GSC features demonstrates the interest in considering oHSV/P2G as a promising new therapeutic approach for glioblastoma patients.
Full text 1,345 characters · extracted from oa-doi-fallback · click to expand
ABSTRACT Glioblastoma is one of the most aggressive brain tumors. Despite the standard therapy, the survival from diagnosis remains dramatically low, especially due to relapses. Considering their capacity to escape the tumor and to migrate to the subventricular zone through a CXCR4-dependant mechanism, Glioblastoma stem-like cells (GSCs) are considered as responsible for these relapses. CXCR4 regulates biological features associated with tumor progression, including self-renewal, migration and radio-resistance. Importantly, its expression correlates with severity and poor prognosis of several cancers including GBM. CXCR4/CXCL12 pathway appears therefore as an interesting potential therapeutic target. We have generated an oncolytic herpesvirus (oHSV) expressing HA-P2G, a mutated form of CXCL12 previously described as a CXCR4 competitive inhibitor. We demonstrate that in vitro, oHSV/P2G impairs human primary GSCs’ stemness markers expression, self-renewal and migration. In an orthotopic xenograft murine model, its injection within the tumor limits tumor growth and GSCs migration. The ability of P2G to interfere with major GSC features demonstrates the interest in considering oHSV/P2G as a promising new therapeutic approach for glioblastoma patients. Competing Interest Statement The authors have declared no competing interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00